Navigation Links
CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
Date:10/27/2008

associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of demyelinating disease. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA; the causal relationship to CIMZIA remains unclear. Exercise caution in considering the use of CIMZIA in patients with these disorders.

Rare reports of pancytopenia, including aplastic anemia, have been reported with TNF blockers. Medically significant cytopenia (e.g., leukopenia, pancytopenia, thrombocytopenia) has been infrequently reported with CIMZIA. The causal relationship of these events to CIMZIA remains unclear. Advise all patients to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g., persistent fever, bruising, bleeding, pallor) while on CIMZIA. Consider discontinuation of CIMZIA therapy in patients with confirmed significant hematologic abnormalities.

Serious infections were seen in clinical studies with concurrent use of anakinra (an interleukin-1 antagonist) and another TNF blocker, with no added benefit. Therefore, the combination of CIMZIA and anakinra is not recommended.

Interference with certain coagulation assays has been detected in patients treated with CIMZIA. There is no evidence that CIMZIA therapy has an effect on in vivo coagulation.

Cases of worsening congestive heart failure (CHF) and new onset CHF have been reported with TNF blockers. CIMZIA has not been formally studied in patients with CHF. Exercise caution when using CIMZIA in patients who have heart failure and monitor them carefully.

Treatment with CIMZIA may result in the formation of autoantibodies and, rarely, in the development of a lupus-like syndrome. Discontinue treatment if symptoms of lupus-like syndrome develop.

Do not administer live vaccines or attenuated vaccines concurrently w
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
2. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
3. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
4. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
5. Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients
6. Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project
7. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
8. Fralex provides update on timing of interim analysis results
9. Vanda Pharmaceuticals Provides Update on Iloperidone
10. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... Singh , Chief Business Officer and Executive Vice President. Mr. ... July 30. "Sorrento is deeply saddened and shocked ... immediate thoughts go to Amar,s family and friends," said ... Mr. Singh joined Sorrento in January 2014 ...
(Date:7/31/2014)... RMD ) today announced results for its fourth ... Revenue for the quarter was $415.2 million, flat compared to ... on a constant currency basis). Net income was $87.7 million, ... June 30, 2013. Diluted earnings per share for the quarter ... quarter ended June 30, 2013.  The results ...
(Date:7/31/2014)... 31, 2014 Pharmacyclics, Inc. (the "Company") (Nasdaq: ... for the quarter ended June 30, 2014. Financial ... 2014 Revenue Total revenue for the quarter ended June ... the quarter ended June 30, 2013 primarily due to IMBRUVICA ... Total revenue for the six months ended June ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23
... 2011 B. Braun Medical Inc. (B. Braun) is part ... the world -- it,s also one of the Best ... and Diagnostic Industry (MD+DI) magazine. One of just 10 ... "must be doing something right." (Logo: http://photos.prnewswire.com/prnh/20081022/NYW008LOGO) ...
... and WASHINGTON, June 15, 2011 The National ... CORE ® (Committee on Operating Rules for Information ... activities related to harmonizing electronic data interchange standards and ... NCPDP and CAQH CORE began exploring the potential partnership ...
Cached Medicine Technology:B. Braun Medical Inc. Named Best Company to Work For 2NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 2NCPDP and CAQH CORE Partner on Harmonizing Operating Rules and Standards Across Healthcare 3
(Date:8/1/2014)... The successful development of C60F projects is of ... Automobile Co.,LTD. As early as the very beginning of ... excellent team to develop a comprehensive plan to carry ... The company’s vice president Liming Yang and some of ... the specific arrangement and the supervision of the project ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Cannabis use among ... teens aged 14 to 17 having used marijuana at least ... With their slogan “Say ‘No’ to Drugs, Say ‘Yes to ... reaching out to youth this summer with factual information about ... past six months, Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ ...
(Date:8/1/2014)... California, San Diego School of Medicine report that dietary ... produces chronic activation of a receptor on cells lining ... reduces the risk of colorectal tumors. , The findings ... The Journal of Clinical Investigation . , The ... in sensory neurons, where it acts as a sentinel ...
(Date:8/1/2014)... a central role in regulating appetite and whole-body metabolism. ... brain,s control of food intake and body weight, but ... been unclear. A new study in the ... activity in a type of neuron known as pro-opiomelanocortin ... high-fat diet. Sabrina Diano and colleagues at Yale ...
(Date:8/1/2014)... HealthDay Reporter FRIDAY, Aug. 1, 2014 ... jobs may have significantly less endurance than those who weigh less, ... -- half were obese, half were of normal weight -- people ... percent longer. Obesity also was associated with less strength, increased ... -- 50 to 65 years of age -- neither improved nor ...
Breaking Medicine News(10 mins):Health News:FODAY Automobile Company Is Now Working On The C60F FODAY Project 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Obesity Might Slow You Down at Work 2Health News:Obesity Might Slow You Down at Work 3
... do-good TV reality show highlighting the need for more organ ... Amid a swirl of controversy, a Dutch channel Friday was ... receive her kidney. ,The controversy stirred by "The ... Netherlands, but public broadcaster BNN is determined to go ahead. ...
... Despite billions of dollars spent on national security in airports, ... allowed to travel unhindered into the United States, underscoring ... a bioterrorist attack against the U.S. ,The attention this ... no surprise, but it's just a glimpse of the potential ...
... years in a coma has woken up and will now have to ... a television station announced Friday. ,Railwayman Jan Grzebski fell ... the private channel Polsat said. In an interview, Grzebski said that he ... who always took care of me. She saved my life," he said. ...
... long court procedure and family disputes regarding the latest woman ... actor's health , say his close friends and well-wishers. ... happen,' a close friend told IANS. ,The actor ... a state of acute pain. ,'Two of the ...
... dump in Khamisiyah, Iraq in March 1991, the soldiers concerned ... much later it was revealed they could have been exposed ... ,Sarin is a chemical weapon estimated to be over ... permanent neurological damage and symptoms such as loss of memory, ...
... oriented professional medical search engines that contain only ... a new professional medical search engine that will ... most timely and relevant clinical information easily accessible ... the new search engine at Chicago's McCormick Place, ...
Cached Medicine News:Health News:Shock TV Reality Organ Donor Show Goes on Air 2Health News:Shock TV Reality Organ Donor Show Goes on Air 3Health News:New Strains of TB Can Be Used as a Powerful Bioterror Weapon 2Health News:New Strains of TB Can Be Used as a Powerful Bioterror Weapon 3Health News:Stress-Related Health Problems Haunts Sanjay Dutt 2Health News:Activists Urge Greater Medical Support for Gulf War Veterans Exposed to Sarin Gas 2Health News:Activists Urge Greater Medical Support for Gulf War Veterans Exposed to Sarin Gas 3Health News:Activists Urge Greater Medical Support for Gulf War Veterans Exposed to Sarin Gas 4Health News:CMPMedica Adds Oncology Search Engine to SearchMedica.com 2
... Parathyroid hormone (PTH) is synthesized ... secreted in response to decreased extracellular ... enhancing bone resorption and decreasing calcium ... into the circulation, intact PTH is ...
... the adrenal cortex and, to a lesser ... a precursor in testosterone and estrogen synthesis, ... at ~10% that of testosterone [1]. However, ... women, DHEA is an important androgen as ...
... steroid, is one of the most potent ... testosterone is secreted primarily by the testes ... peripheral conversion of androstenedione [2]. In adult ... 50% of serum testosterone is derived from ...
... Thyroxine (T4) is the primary active ... the thyroid gland [1]. T4 is synthesized ... iodide trapping by the follicular cells, (ii) ... substrate leading to formation of 3-monoiodotyrosine and ...
Medicine Products: